Liu Ming, He Wen-Xin, Song Nan, Yang Yang, Zhang Peng, Jiang Ge-Ning
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Eur J Cardiothorac Surg. 2016 Nov;50(5):909-913. doi: 10.1093/ejcts/ezw113. Epub 2016 Mar 31.
To identify epidermal growth factor receptor (EGFR) mutation status between different lesions in lung adenocarcinoma presenting as multiple ground-glass opacity (GGO) lesions and analyse its association with clinical characteristics.
Seventy-eight patients with lung adenocarcinoma presenting as multiple GGO lesions were identified to investigate EGFR mutation in exon 18-21. Lesions with the largest size in diameter were defined as the primary lesions; the others were defined as the secondary lesions. One hundred and fifty-nine lesions of these patients were classified into pure GGO and mixed GGO by computed tomography scan images.
The EGFR mutation rate in the patients was 48.7% (38 of 78). Patients with high frequency of EGFR mutation were females and non-smokers. The EGFR mutation rate of invasive adenocarcinoma was higher than that of atypical adenomatous hyperplasia/adenocarcinoma in situ and minimally invasive adenocarcinoma (P = 0.001). Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma. Of the 38 paired lesions in patients harbouring EGFR mutation, the discordance rate of EGFR mutation was 92.1%.
The study showed different EGFR mutational profiles in multiple GGO lesions, suggesting that lesions seem to arise as independent events. It would offer useful information for determining the appropriate treatment strategy for lung adenocarcinoma presenting as multiple GGO lesions.
明确表现为多发磨玻璃影(GGO)的肺腺癌不同病灶间表皮生长因子受体(EGFR)突变状态,并分析其与临床特征的相关性。
纳入78例表现为多发GGO病灶的肺腺癌患者,检测其第18 - 21外显子的EGFR突变情况。将直径最大的病灶定义为原发灶,其他病灶定义为继发灶。通过计算机断层扫描图像将这些患者的159个病灶分为纯GGO和混合GGO。
患者的EGFR突变率为48.7%(78例中的38例)。EGFR突变频率高的患者为女性且不吸烟。浸润性腺癌的EGFR突变率高于非典型腺瘤样增生/原位腺癌和微浸润性腺癌(P = 0.001)。虽然19号外显子缺失和L858R是最常见的EGFR突变,但腺癌病理亚型间的EGFR突变无差异。在38例携带EGFR突变患者的配对病灶中,EGFR突变不一致率为92.1%。
本研究显示多发GGO病灶中存在不同的EGFR突变谱,提示病灶似乎是独立发生的。这将为确定表现为多发GGO病灶的肺腺癌的合适治疗策略提供有用信息。